Streetbeat News

Stock Prices

CRWD

A financial giant has made a bearish move on CrowdStrike Holdings (NASDAQ:CRWD), with 63% of traders showing bearish tendencies. The major market movers are focusing on a price band between $50.0 and $230.0 for CrowdStrike Holdings. Argus Research downgraded its rating to Buy, setting a price target of $220. JMP Securities revised its rating downward to Market Outperform, adjusting the price target to $235. Jefferies upgraded their rating to Buy and adjusted the price target to $225.

Portfolio Pulse from Benzinga Insights

November 08, 2023 | 7:15 pm

LLY

Eli Lilly's shares are trading higher following the FDA's approval of Zepbound for chronic weight management.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 7:14 pm

TTWO

Take-Two Interactive's (NASDAQ:TTWO) stock rose following the announcement of the first trailer for the next Grand Theft Auto game by its subsidiary, Rockstar Games. The Grand Theft Auto series has a history of successful releases, with the last entry selling 185 million copies since 2013. The announcement has generated significant attention on social media. Take-Two is also set to release its Q3 financial statement, with analysts expecting an EPS of $1.04 and revenue of $1.41 billion.

Portfolio Pulse from Franca Quarneti

November 08, 2023 | 7:11 pm

INVZ

MBLY

Citron Research has expressed optimism about Innoviz Technologies (INVZ), predicting that Mobileye could potentially acquire the company at a significantly higher price. The company is currently trading at a small premium to cash, with a strong position in the LIDAR industry. Despite recent events in Israel, Innoviz's global operations have continued as planned.

Portfolio Pulse from Benzinga Newsdesk

November 08, 2023 | 7:04 pm

LLY

NVO

The FDA has approved Eli Lilly's Zepbound (tirzepatide) injection for obesity treatment, which is expected to be available in the U.S. by the end of the year. The drug is priced approximately 20% lower than Nova Nordisk's semaglutide 2.4 mg injection for weight loss. Eli Lilly's shares are up 1.99% following the news.

Portfolio Pulse from Vandana Singh

November 08, 2023 | 7:04 pm

NXST

Nexstar Media Group Inc (NASDAQ:NXST) reported a Q3 FY23 net revenue decline of 10.8% Y/Y to $1.13 billion, missing the consensus of $1.17 billion. The decline was due to a decrease in cyclical political advertising and the temporary removal of stations from an MVPD. Television Advertising revenues fell 22.5% Y/Y to $410 million. The company returned $246 million to shareholders through repurchases worth $199 million and quarterly cash dividend payments of $47 million. Nexstar shares are trading lower by 3.15% at $146.69.

Portfolio Pulse from Lekha Gupta

November 08, 2023 | 7:03 pm

DASH

A significant investor has taken a bearish stance on DoorDash (NASDAQ:DASH), as indicated by a large position in the company's options. The overall sentiment of these big-money traders is split between 40% bullish and 60% bearish. The significant investors are aiming for a price territory stretching from $60.0 to $95.0 for DoorDash over the recent three months. Currently, DASH's price is down by -0.83%, now at $88.17.

Portfolio Pulse from Benzinga Insights

November 08, 2023 | 7:02 pm

PFE

A significant bearish move has been observed in Pfizer's (NYSE:PFE) recent unusual options activity. Analysis revealed 70% of traders showed bearish tendencies, with 7 puts valued at $8,504,440 and 3 calls valued at $80,240. Major market movers are focusing on a price band between $20.0 and $50.0 for Pfizer. Trading volume stands at 13,151,033, with PFE's price down -2.0%, positioned at $30.62. Analysts from Barclays, UBS, Citigroup, JP Morgan, and Wells Fargo maintain neutral to equal-weight ratings on Pfizer with target prices around $34-$35.

Portfolio Pulse from Benzinga Insights

November 08, 2023 | 7:02 pm

BIOL

Biolase (NASDAQ:BIOL) is set to release its latest quarterly earnings report on November 9, 2023. Analysts estimate an earnings per share (EPS) of $-1.85. The company's stock price has historically been affected by its earnings performance and guidance. Last quarter, Biolase beat EPS by $1.09, resulting in a 13.87% drop in share price the next day. The company's shares are currently trading at $1.58 and have dropped 99.01% over the last 52-week period.

Portfolio Pulse from Benzinga Insights

November 08, 2023 | 7:02 pm

CURI

CuriosityStream (NASDAQ:CURI) is set to release its quarterly earnings report on November 9, 2023. Analysts estimate an earnings per share (EPS) of $-0.15. The company's past performance shows a trend of missing EPS estimates, which has led to drops in share price. The stock is currently trading at $0.59, down 60.13% over the last 52-week period.

Portfolio Pulse from Benzinga Insights

November 08, 2023 | 7:02 pm